A study to evaluate the efficacy and safety of two doses of Anifrolumab compared to placebo in adult patients with Active Systemic Lupus Erythematosus

Phase 1

• Conditions: Systemic Lupus Erythematosus; MedDRA version: 21.1 Level: PT Classification code 10042945 Term: Systemic lupus erythematosus System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders; Therapeutic area: Diseases [C] - Immune System Diseases [C20]

• Registration Number: EUCTR2014-004633-96-IT
• Lead Sponsor: ASTRAZENECA AB

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-08-23
• Study Start: 2020-01-21
• Last Update Posted: 1 February 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 457

Inclusion Criteria

1. Aged 18 through 70 years at the time of screening
2. Diagnosis of paediatric or adult SLE with a diagnosis of SLE according
XML File Identifier: q9pJEsCaieOmWi8NgbgYJXtqfj8=
Page 14/25
to the ACR 1982 revised criteria =24 weeks prior to signing the Informed
Consent form (ICF)
3. Currently receiving at least 1 of the following:
(a) A dose of oral prednisone (=40 mg/day) for a minimum of 2 weeks
prior to signing of the ICF.
(b) Any of the following medications administered for a minimum of 12
weeks prior to signing the informed consent, and at a stable dose for a
minimum of 8 weeks prior to signing the informed consent and until Day
1:
(i) Azathioprine =200 mg/day
(ii) Antimalarial (eg, chloroquine, hydroxychloroquine, quinacrine)
(iii) Mycophenolate mofetil =2 g/day or mycophenolic acid =1.44 g/day
(iv) Oral, subcutaneous (SC), or intramuscular methotrexate =25
mg/week
(v) Mizoribine =150 mg/day
4. Fulfils at least 4 of the 11 ACR modified 1982 classification criteria for
SLE, at least 1 of which must be:
(a) Positive antinuclear antibody (ANA) test at screening by
immunofluorescent assay (IFA) at the central laboratory with titre =
1:80; OR
(b) Elevated anti-dsDNA antibodies OR anti-Smith (anti-Sm) antibody at
screening as determined by the central laboratory
5. At Screening, Disease Activity Adjudication Group confirmation of:
SLEDAI-2K Criteria: SLEDAI-2K score =6 points and Clinical SLEDAI-2K
score =4 points. The Clinical SLEDAI-2K is the SLEDAI-2K assessment
score without the inclusion of points attributable to any urine or
laboratory results including immunologic measures:
6. Must not have active or latent TB on either chest radiograph or by
quantiferon gold test
7. Day 1 Clinical SLEDAI-2K score =4 points
8. OCS dose stable for at least 2 weeks
9. Stable SLE SOC treatment
10. Women of child-bearing potential must have a negative serum ß-hCG
test at screening and negative urine pregnancy test prior to
administration of investigational product
Are the trial subjects under 18? no
Number of subjects for this age range: 1
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 338
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 112

Exclusion Criteria

1. Receipt of any investigational product (small molecule or biologic
agent) within 4 weeks or 5 half-lives prior to signing of the ICF,
whichever is greater
2. Receipt of any of the following:
(a) Intra-articular, intramuscular or IV glucocorticosteroids within 6
weeks
prior to Day 1
3. History of, or current diagnosis of, a clinically significant non SLErelated
vasculitis syndrome. 4. Active severe or unstable
neuropsychiatric SLE
5. Active severe SLE-driven renal disease
6. Diagnosis (within 1 year of signing the ICF) of mixed connective
tissue disease or any history of overlap syndromes of SLE or SSc.
7. History of, or current, inflammatory joint or skin disease other than
SLE
8. History of any non-SLE disease that has required treatment with oral
or parenteral corticosteroids for more than 2 weeks within the 24 weeks
prior to enrollment
9. Confirmed positive test for hepatitis B or hepatitis C
10. Any severe herpes infection at any time prior to Week 0 (Day 1)
11. Opportunistic infection requiring hospitalisation or parenteral
XML File Identifier: q9pJEsCaieOmWi8NgbgYJXtqfj8=
Page 15/25
antimicrobial treatment within 3 years prior to randomization
12. History of cancer, apart from:
(a) Squamous or basal cell carcinoma of the skin that has been
successfully treated
(b) Cervical cancer in situ that has been successfully treated

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified